Jul 20, 2026 11:36AM

May 28, 2026 08:00AM

Feb 25, 2026 08:00AM

Oct 30, 2025 08:00AM

May 27, 2025 08:00AM

Feb 25, 2025 08:00AM

Dec 13, 2024 05:16PM NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters’ Option to Purchase Additional

Dec 11, 2024 09:37PM

Dec 10, 2024 04:36PM

Dec 10, 2024 04:34PM

Oct 28, 2024 04:30PM

May 29, 2024 08:00AM

Feb 26, 2024 08:00AM

Feb 14, 2024 05:47AM NewAmsterdam Pharma (NAMS) Prices 4.49M Share Offering at $19/sh

Feb 13, 2024 10:40PM

Feb 13, 2024 04:01PM

Feb 13, 2024 04:01PM

Nov 13, 2023 08:00AM

Jun 9, 2023 04:01PM

Jun 7, 2023 05:17AM

Jun 6, 2023 11:25PM NewAmsterdam Pharma Announces Pricing of Upsized Secondary Offering of Ordinary Shares

Jun 6, 2023 04:02PM

Jun 6, 2023 04:01PM

May 31, 2023 08:00AM

Dec 19, 2022 08:26AM

Nov 23, 2022 08:03AM

Nov 23, 2022 08:00AM

Nov 23, 2022 08:00AM NewAmsterdam Pharma Debuts as Publicly Traded Company Focused on Developing Obicetrapib, a Low-Dose, Once-Daily Oral LDL-Lowering Agent with Promising Safety and Efficacy Clinical Data, as a Potential

72,900 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All